Neurological disorders: organoids for early drug discovery

29 May 2024


Join us for this webinar as we explore the role of organoids in advancing treatment of neurological disorders. Organoids, miniature 3D models of human organs, are at the forefront of neuroscience research, offering insights into the complexities of the human brain. In this webinar, esteemed experts will explore the latest breakthroughs in organoid technology and their application in early drug discovery for neurological conditions.

Watch this webinar to learn about organoids in neuroscience research and the future of this field.
Featured in this webinar, we will discuss:

1. Organoids: building blocks of brain research: gain a comprehensive understanding of organoid technology and its significance in modelling neurological disorders.
2. Modelling neurological disorders: discover how organoids are being used to recreate the pathophysiology of diseases such as Alzheimer’s, Parkinson’s, and autism spectrum disorders.
3. Drug screening and development: explore the use of organoids for high-throughput drug screening and the development of novel therapeutics targeting neurological conditions.
4. Overcoming challenges: learn about the current limitations of organoid technology and ongoing efforts to enhance their relevance and reproducibility in drug discovery.
5. Future perspectives: gain insights into the future directions of organoid research.

Register now to secure your seat.


Dr M Ángeles Rabadán, Founder and Chief Executive Officer

ZENEUROID is pioneering the development of innovative therapies for neuropathic and neurodegenerative diseases, offering a groundbreaking neuroid technology. Their advanced 3D cultures of interconnected neuroids mimic neuronal networks, surpassing traditional methods and enabling non-invasive, animal-free studies across diverse disorders. By combining genetic and cellular bioengineering with human reprogramming technologies, they accurately model patient genetic profiles. Initially focused on epilepsy, schizophrenia, and Parkinson’s disease, the company plans to expand to autism, Alzheimer’s, and rare diseases. Currently supported by ZeLife Enterprises, ZENEUROID strives to excel as a Contract Research Organization (CRO), serving biotech, pharma, and academic institutions to advance research and treatment development in neurological diseases. The company will provide cellular reprogramming, neural differentiation, and drug screening services.

Dr Rabadan is the Founder and Chief Executive Officer of Zeneuroid. She holds a diverse academic background in Cell Biology, Developmental biology, Neurobiology, and Genetics, having held several positions at leading international research institutions, including the University College of London, the Memorial Sloan Kettering Cancer Center in New York, Columbia University and the Biology and Molecular Institute of Barcelona (CSIC). As part of her research, she has focused on developing innovative in vitro methodologies to advance the understanding of human brain function having gained deep insights into organoids and human stem cell research. Her groundbreaking work led to the creation of novel modular neuronal networks, accurately replicating the functional and structural complexities of the brain, resulting in a patented tool in 2019, which formed the base of ZENEUROID”s technology.

Dr Rabadan holds a PhD from the Biology and Molecular Institute of Barcelona (CSIC). She has published 15 publications, and her research has garnered widespread recognition, having been featured in numerous international conferences, often as an invited speaker.

DTR webinar headshot

Radhika Menon, PhD is a Senior Scientist at Ncardia, Leiden

In her current position, she leads projects involving human induced pluripotent stem cells (iPSCs) and various iPSC-derived cell types. She started her scientific career as a Junior Researcher in India where she worked on human iPSCs and (embryonic stem cells) ESCs and a cellular model for Alzheimer’s Disease. She received her PhD in Translational Neuroscience from the Johannes Gutenberg University, Mainz, Germany, working under the supervision of Prof. Marisa Karow and Prof. Benedikt Berninger. Her PhD project involved the establishment and characterization of an iPSC-derived brain organoid model to study a neurodevelopmental disorder (Opitz Syndrome). Her motivation to do impactful work in the fields of disease modelling, drug development and patient care guided her move to industry to pursue translational research. She moved to the Netherlands to join Mimetas, an organ-on-a-chip company, where she worked with human neuronal, cancer and intestinal biology systems. Dr. Menon’s expertise in cellular differentiation (2D & 3D) and disease modelling in various therapeutic areas is leveraged at Ncardia for cell manufacture and model development services.




Is the webinar free? 

Yes – there is no charge to watch the webinar, either live or on-demand. 

When will the webinar take place? 

29th May 2024 at 3.00pm BST. 

Can I watch it later? 

The webinar will become available to watch on-demand shortly after the live webinar takes place. 

What are the benefits of attending live? 

You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session. 

How long will the webinar be? 

This webinar will last up to an hour. 

What do I need to watch this webinar? 

All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.